MedTrace Logo

Convalescent Plasma in the Treatment of Covid-19

NCT04600440 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-23

No results posted yet for this study

Summary

One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary treatment.

Primary outcome is number of days the patients need oxygen within 28 days from inclusion.

Secondary outcome is number of days in hospital, number of days in respirator and mortality.

Side effects of treatment is monitored.

Conditions

Interventions

BIOLOGICAL

Convalescent plasma

Plasma donated from patients recovered from Covid-19 and having high titres of antibodies

Sponsors & Collaborators

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Mona Landin-Olsson, MD, Prof · Skane University Hospital

  • Maria N Lundgren, MD · Skane University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-25
Primary Completion
2021-12-31
Completion
2022-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04600440 on ClinicalTrials.gov